Approaches towards menstrual cycle disorder therapy in reproductive-aged women with long COVID

Q4 Medicine
V.V. Kaminskyi, A.V. Serbeniuk, Y.O. Kumpanenko
{"title":"Approaches towards menstrual cycle disorder therapy in reproductive-aged women with long COVID","authors":"V.V. Kaminskyi, A.V. Serbeniuk, Y.O. Kumpanenko","doi":"10.18370/2309-4117.2023.68.44-47","DOIUrl":null,"url":null,"abstract":"Background. The mirror of a female’s reproductive health is the menstrual cycle. The SARS-CoV-2 pandemic itself acts as a significant stressor. This leads to women’s overall health and life quality disturbance. Moreover, patients struggle with long COVID effects, which is a prolongation of symptoms after recovery. Due to the expression of angiotensin-converting enzyme type 2 receptors in the intestinal mucosa and inflammation, the gastrointestinal (GI) tract is also triggered by the virus.Objectives. To assess the efficacy of the chosen treatment approach in women with changes in premenstrual syndrome and cyclicity due to long COVID with or without GI symptoms.Material and methods. A single-centre longitudinal interventional study was organized. Were studied data from the conducted tests (progesterone level, ultrasound follicle scan, etc.) and surveys. Then the effectiveness of the suggested treatment with the use of oral and vaginal forms of progesterone was evaluated. The study was held in the Kyiv City Center of Reproductive and Perinatal Medicine (Ukraine) from January to June 2021.Results. On average 78% patients without GI symptoms experienced relief after 3 months and 89% patients after 6 months of suggested treatment. 71% patients with GI symptoms experienced improvement after 3 and 87% of them after 6 months. The vaginal progesterone had better results compared to oral form. Averagely 6–8% experienced side effects (nausea, hypotension, less compliance) due to progesterone intake. The vaginal micronised progesterone also presented better results than oral with fewer side effects compared to the total number of participants.Conclusions. The proposed approach has shown particular correction of the menstrual cycle disturbances in women with long COVID. Vaginal micronized progesterone offers more promising outcomes in patients with GI symptoms and disrupted absorption, compared to the oral form.Further investigation is required for a more reasonable conclusion.","PeriodicalId":21103,"journal":{"name":"Reproductive Endocrinology","volume":"166 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18370/2309-4117.2023.68.44-47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background. The mirror of a female’s reproductive health is the menstrual cycle. The SARS-CoV-2 pandemic itself acts as a significant stressor. This leads to women’s overall health and life quality disturbance. Moreover, patients struggle with long COVID effects, which is a prolongation of symptoms after recovery. Due to the expression of angiotensin-converting enzyme type 2 receptors in the intestinal mucosa and inflammation, the gastrointestinal (GI) tract is also triggered by the virus.Objectives. To assess the efficacy of the chosen treatment approach in women with changes in premenstrual syndrome and cyclicity due to long COVID with or without GI symptoms.Material and methods. A single-centre longitudinal interventional study was organized. Were studied data from the conducted tests (progesterone level, ultrasound follicle scan, etc.) and surveys. Then the effectiveness of the suggested treatment with the use of oral and vaginal forms of progesterone was evaluated. The study was held in the Kyiv City Center of Reproductive and Perinatal Medicine (Ukraine) from January to June 2021.Results. On average 78% patients without GI symptoms experienced relief after 3 months and 89% patients after 6 months of suggested treatment. 71% patients with GI symptoms experienced improvement after 3 and 87% of them after 6 months. The vaginal progesterone had better results compared to oral form. Averagely 6–8% experienced side effects (nausea, hypotension, less compliance) due to progesterone intake. The vaginal micronised progesterone also presented better results than oral with fewer side effects compared to the total number of participants.Conclusions. The proposed approach has shown particular correction of the menstrual cycle disturbances in women with long COVID. Vaginal micronized progesterone offers more promising outcomes in patients with GI symptoms and disrupted absorption, compared to the oral form.Further investigation is required for a more reasonable conclusion.
育龄期长COVID妇女月经周期紊乱的治疗方法探讨
背景。女性生殖健康的镜子是月经周期。SARS-CoV-2大流行本身就是一个重要的压力源。这导致妇女的整体健康和生活质量受到干扰。此外,患者在康复后的症状延长,也就是长期的COVID效应。由于血管紧张素转换酶2型受体在肠粘膜和炎症中的表达,胃肠道(GI)也可被病毒触发。评估所选择的治疗方法在伴有或不伴有胃肠道症状的长期COVID所致经前综合征和周期改变的女性中的疗效。材料和方法。组织了一项单中心纵向介入研究。研究了已进行的测试(黄体酮水平、超声卵泡扫描等)和调查的数据。然后评估口服和阴道形式的黄体酮建议治疗的有效性。该研究于2021年1月至6月在乌克兰基辅市生殖和围产期医学中心进行。平均78%没有胃肠道症状的患者在3个月后得到缓解,89%的患者在建议治疗6个月后得到缓解。71%的胃肠道症状患者在3个月后得到改善,87%的患者在6个月后得到改善。阴道黄体酮比口服黄体酮效果更好。平均6-8%的患者因服用黄体酮而出现副作用(恶心、低血压、依从性降低)。阴道微化黄体酮也比口服效果更好,副作用较少。所提出的方法对长COVID妇女的月经周期紊乱有特别的纠正作用。与口服形式相比,阴道微粉黄体酮在胃肠道症状和吸收中断的患者中提供了更有希望的结果。需要进一步调查才能得出更合理的结论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reproductive Endocrinology
Reproductive Endocrinology Medicine-Obstetrics and Gynecology
CiteScore
0.50
自引率
0.00%
发文量
13
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信